
Please try another search
As of June 29, 2023, VectivBio Holding AG was acquired by Ironwood Pharmaceuticals, Inc. VectivBio Holding AG, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes medicines to treat severe gastrointestinal conditions. The company’s product apraglutide currently undergoes Phase III clinical trials for the treatment of patients suffers from short bowel syndrome-intestinal failure (SBS-IF). Additionally, it participates in Phase II clinical trials for SBS-IF in patients with colon-in-continuity anatomy and for patients with steroid-refractory gastrointestinal acute graft versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review